The University of Newcastle is the overall coordinator of the MCDS-Therapy project. The team is responsible for the day-to-day running of the project, including planning, monitoring, reporting, and managing relations between all partners and funders.
Alongside project coordination, the University is playing a large role in other aspects of the trial, including:
- Leading and coordinating all phases of the clinical trial.
- Assessing the health economics of MCDS. This means estimating the current cost of MCDS and the impact of the treatment on this. If carbamazepine successfully treats patients, it is more likely to be paid for by the health service if is cost effective.
- Developing commercialisation strategies. Discoveries made by the various research partners could be sold to other organisations and groups, helping to recuperate some of the costs of the trial.
- Making sure the project is run ethically, with patients and families in mind.
This work is carried out across the Institute of Genetic Medicine (IGM), the Institute of Health and Society (IHS), and the University’s Clinical Trials Unit (CTU). Together, these institutes have a critical mass of experienced scientists, clinicians, pharmacists and statisticians.